Abstract A thorough understanding of histone acetyltransferase CBP/p300-mediated regulation of gene expression and cell growth is essential to identify mechanisms relevant to the development of histone deacetylase (HDAC) inhibitor-based preventive and therapeutic strategies. We found that knockdown of CBP/p300 interacting coactivator with glutamic acid/aspartic acid-rich tail 2 (CITED2) increased colon cancer cell invasiveness in vitro. Gene expression profiling revealed that CITED2 knockdown induced matrix metalloproteinase-13 (MMP-13) gene expression in colon cancer cells. Butyrate, a naturally occurring HDAC inhibitor, induced CITED2 expression and downregulated MMP-13 expression in RKO cells. Additionally, ectopic expression of CITED2 arrested RKO cell growth. Thus, CITED2 regulates colon cancer invasion and might be a target for HDAC inhibitor-based intervention of colon cancer.
Introduction
Colon cancer is the second leading cause of cancer death in the United States. Colorectal cancer commonly metastasizes to the liver [1] , and as with most cancers, it is the metastasis that is mainly responsible for high mortality rates. Thus, elucidation of the mechanisms responsible for initiation, progression and eventually metastasis of colon cancer metastases is required for the ultimate control of this disease. Evolution of the metastatic phenotype requires enhanced cell invasiveness to enable the tumor cell to separate from the primary site and successfully establish a metastatic colony [2] . Unlike the molecular events described for the pathogenesis of primary colon tumors, the genes and pathways responsible for metastasis in these tumors have not been well characterized.
Aberrant gene expression due to epigenetic changes has been postulated to be a driving force underlying tumor progression, and histone deacetylase (HDAC) and DNA methyltransferase inhibitors-based epigenetic therapy has emerged as a reliable approach for the intervention of cancer [3] . Functional CBP/ p300 is critical for transcriptional regulation of gene expression and control of cell growth [4, 5] . CBP/p300 loss-of-function is associated with a variety of malignant cancers, including colon cancer [6] [7] [8] . In the human colon cancer cell line HCT116, p300 deletion leads to aggressive ''cancer'' phenotypes, including increased migration and invasion in vitro [9] .
CBP/p300 interacting coactivator with glutamic acid/aspartic acid-rich tail 2 (CITED2) is a bifunctional protein that belongs to a family of transcriptional cofactors that is characterized by a conserved ED-rich domain at the C-terminus. A functional motif (LPXL) within this domain is necessary and sufficient for binding to the first cysteine-histidine-rich region of CBP/p300 [10] . Initially described as a corepressor of hypoxia-inducing factor 1a (HIF1a) by competing for CBP/p300 binding [11] , CITED2 also functions as a coactivator of activator protein 2 (AP-2) [12] , PPARa and PPARc [13] , and LIMhomeodomain protein Lhx2 [14] by recruiting CBP/p300. Loss of CITED2 in mice results in embryonic lethality -a consequence of multiple developmental defects [15, 16] . Ectopic expression of melanocyte-specific gene related gene (MRG1), an alternatively spliced isoform of CITED2, results in oncogenic transformation in rat fibroblasts [17] . However, it is not clear if CITED2 functions as a tumor-promoter or suppressor. A recent study showed that knockdown of CITED2 in the breast cancer cell line MDA-MB-231 attenuates TGFb1-mediated upregulation of matrix metalloproteinase-9 (MMP-9) and cell invasiveness in vitro [18] . This study raised the possibility that CITED2 affects tumorigenesis by modulating tumor invasion rather than proliferation. Using CITED2 specific small hairpin (sh) RNA to knockdown CITED2 expression in human colon cancer cells, we observed that CI-TED2 knockdown induced changes in cell morphology, concomitant with increased cancer cell invasiveness in vitro. Our results suggest a pivotal role for CITED2 in colon cancer cell growth regulation and may have important implications in targeting CITED2 for nutrition-based chemoprevention and chemotherapy for colon cancer.
Materials and methods

Reagents
Monoclonal antibody against p21 waf1 and rabbit polyclonal antibody against HDAC1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit polyclonal antibody against acetyl-H2A Abbreviations: CITED2, CBP/p300 interacting coactivator with glutamic acid/aspartic acid-rich tail 2; MMP, matrix metalloproteinase; HDAC, histone deacetylase was obtained from Cell Signaling (Danvers, MA); mouse monoclonal anti-CITED2 (JA22) was obtained from Novus Biologicals (Littleton, CO); and mouse monoclonal anti-b-catenin was obtained from BD Biosciences Pharmingen. A control scrambled siRNA was obtained from Ambion (Austin, TX).
Plasmids
The pMK17, which contains 598 bp of human CITED2 proximal promoter, was kindly provided by Dr. Shoumo Bhattacharya (University of Oxford). The plko1 lentiviral vector or plko1-shCITED2 which expresses shRNA targeting the human CITED2 cDNA coding region from +428 to +448 nt (BC004377) were obtained from the Open Biosystems (Huntsville, AL). The lentiviruses were produced at the University of Michigan Vector Core. The pOBT7-CITED2, which contains the full-length human CITED2 cDNA was purchased from the Origene (Rockville, MD). To generate HA-tagged CITED2 expression vector, the following primers were used to amplify full-length CITED2 cDNA using the pOBT7-CITED2 as the template. Forward:
0 . The PCR fragments were digested with Hind III and inserted into the pCMV10 vector and verified by sequencing. The expression of HA-CITED2 was verified by immunoblots.
Cell culture
The human colon cancer cell line RKO was purchased from the ATCC (Manassas, VA) and cultured in minimum essential medium with 10% fetal bovine serum. To generate CITED2 knockdown stable cell line, RKO cells were transduced with lentiviral empty vector or CI-TED2 shRNA expressing vector and selected with puromycin at 0.1 lg/ml for 3-4 weeks. The pools of puromycin-resistant cells were used for further analyses. To generate stable cell line that expresses HA-tagged CITED2, cells were transfected with pCMV10 vector or pCMV10-HA-CITED2 vector and selected with G418 at 0.5 mg/ml for 3 weeks. The pools of G418-resistant cells were used for further analyses.
Reporter assay
Cells cultured in 48-well plates were transfected with human CI-TED2 reporter pMK17 using FUGENE 6 (Roche). The cells were treated with 2.5 mM sodium butyrate for 20 h prior to performing luciferase reporter assays that were normalized to protein [19] . Luciferase assay was performed on Perkin-Elmer VICTOR 3 1420 Multilabel Counter using the Luciferase Reporter Assay System (Promega).
Small interfering RNA
RNA interference experiments with small interfering RNA (siRNA) were carried out as described before [20] . The region of CITED2 cDNA targeted for siRNA was: +519 5 0 -AAGGTTTAACAACTCC-CAGTT-3 0 . A scrambled siRNA (Ambion) was used as control. siRNAs were transfected into cells with Oligofectamine (Invitrogen).
RNA isolation and RT-PCR analysis
Total RNA was isolated from cells using RNeasy mini kit (Qiagen) following the manufacturerÕs protocol. First-strand cDNA synthesis was performed using the SuperScript Ò III First-strand Synthesis System (Invitrogen). The sequences of primers and amplification conditions are available upon request.
Matrigel invasion assay
Matrigel invasion assays were performed using BD Matrigel Invasion Chamber (6-well plates, 8 lm pore size, BD Biosciences). Cells were first cultured in serum free medium for 20-24 h, then collected and resuspended in medium with 0.1% BSA at a density of 2.5 · 10 5 cells/ml. Culture medium with 10% FBS was added to the lower chamber and 500 ll of the resuspended cells were added onto the top of the Matrigel. Forty hours later, the non-invaded cells and Matrigel on the topside of the transwell were scrapped off with cotton swab. Cells on the lower surface of the membrane were fixed with methanol, stained with haematoxylin and eosin (H&E) and viewed with Olympus BX60 microscope using SPOT software.
MMP-13 activity assay
Cells were seeded in 12-well plates at a density of 2 · 10 5 /well. Twelve hours later, cells were washed with PBS and incubated in 0.5 mL serum-free medium for another 24 h. The conditional medium was collected, centrifuged at 10 000 rpm for 5 min; and 25 ll of the supernatant was used to detect MMP-13 activity using the SensoLyte Plusä 520 MMP-13 Assay Kit (AnaSpec, San Jose, CA) following the manufacturerÕs instruction. The fluorescence signal was measured by VICTOR 3 Multilabel Counter (Perkin-Elmer) with a filter set of excitation/emission = 495 nm/535 nm.
Confocal microscopy
Cells were fixed in 3.7% formaldehyde solution for 10 min, treated with 0.1% Triton X-100 for 5 min, and incubated with Alexa fluor 488 phalloidin (Molecular Probes, Eugene, OR) for 30 min at room temperature. The cells were mounted and examined with a confocal microscope (Olympus FV-500) at the University of Michigan Microscopy & Image Analysis Lab.
Results and discussion
CITED2 knockdown induced morphological changes in
colon cancer cells To explore the functions of CITED2 in colonic cells, we used CITED2-specific shRNA to knockdown its expression in the colon cancer cell line RKO. As shown in Fig. 1A and B, both CITED2 mRNA and protein levels were significantly reduced by CITED2 shRNA. The expression of CITED4 was not affected (Fig. 1A) , which validated the specificity of CITED2 shRNA. Cells with reduced CITED2 expression induced a flattened morphology compared to the control cells (Fig. 1C) . Notably, a flattened appearance is also a feature of CITED2 (À/À) mouse fibroblasts [21] . To determine whether the morphological changes were associated with alterations in the actin cytoskeleton, the cells were stained with phalloidin. Phalloidin staining revealed cytoskeleton reorganization in CITED2 knockdown RKO cells (Fig. 1D ).
CITED2 knockdown increased colon cancer cell
invasiveness in vitro Actin reorganization is normally associated with changes in cancer cell migration and invasion [22] . Therefore, we assessed whether the morphological changes in CITED2 knockdown cells were accompanied by changes in cell migration and invasion in vitro. Wound healing assays showed that CITED2 knockdown had no affect on cell migration (data not shown). However, the Boyden chamber invasion assay demonstrated that the CITED2 knockdown significantly increased the invasiveness of RKO cells (Fig. 2) . Given the importance of Wnt signaling in colon cancer progression, we examined whether the phenotypic changes in CITED2 knockdown cells were accompanied by alterations in the Wnt/b-catenin pathway. As shown in Fig. 3A , reduced levels of CITED2 had no significant affect on the subcellular localization of b-catenin in RKO cells, nor the expression of b-catenin and TCF (Fig. 3B) . The lack of induction of the b-catenin pathway correlates with the lack of induction of downstream targets, e.g., cyclin D1 and c-myc (Fig. 3B) . Therefore, reduced levels of CITED2 induced phenotypic changes that were independent of the b-catenin/TCF pathway.
CITED2 knockdown upregulated MMP-13 expression
To identify key genes involved in the phenotypic changes in CITED2 knockdown of the RKO cells, we performed DNA microarray analysis using the Affymetrix GeneChip Human U133 Plus 2.0 Array. A total of 739 genes were differentially regulated by a factor of 2.5-fold when CITED2 levels were decreased: 235 genes were upregulated and 504 genes were downregulated. Among the differentially regulated genes, MMP-13 was significantly upregulated in CITED2 knockdown cells (4-fold), suggesting that this metalloproteinase was specifically inhibited by CITED2. To determine whether the upregulation of MMP-13 in CITED2 knockdown cells is an early response of CITED2 knockdown or the consequence of chronic cellular physiological changes, we performed transient siRNA transfection experiments. Total RNA was isolated 20 h after siRNA transfection, and RT-PCR was performed to survey the expression of MMP1-3 and 7-16. Of the MMPs detected in RKO cells, MMP-13 was significantly upregulated by CITED2 silencing (Fig. 4A) . Notably, it has been reported that CITED2 mediates flow shear regulated expression of MMP-1 and MMP-13 in human chondrocytes [18] . However, MMP-9 was essentially undetectable in RKO cells and the levels were not significantly induced in contrast to what has been reported for this target of CITED2 in human breast cancer cell line MDA-MB-231 [18] . Thus regulation of MMP-9 by CITED2 may be cell dependent. Enzyme-linked immunosorbent assay for MMP-13 confirmed that CITED2 knockdown significantly increased the cell levels of MMP-13 protein (data not shown). Accordingly, MMP-13 activity was also significantly increased in the medium of CITED2 knockdown cells (Fig. 4B) . Previous studies have established a critical role for MMPs in colon cancer invasion and metastasis [23] . In particular, elevated MMP-13 expression is associated with poor prognosis in colon cancer [24] . We therefore assessed whether neutralizing MMP13 activity with its antibody blocked RKO cell invasion in vitro. Incubation of cells with the anti-MMP-13 monoclonal antibody VIIA2 (Calbiochem) reduced the invasive capacity of cells expressing reduced levels of CITED2 by $25% (data not shown), suggesting that other changes in CITED2 knockdown cells (e.g., cytoskeletal reorganization) also contribute to the altered invasiveness of these cells.
To investigate whether CITED2 commonly regulates MMP-13 expression in colon cancer cell lines, we silenced CITED2 expression in SW480 colon cancer cells with siRNA. As shown in Fig. 5A , CITED2-specific siRNA reduced CITED2 expression by $70% (Fig. 5A) . Of the 11 MMPs detected in this cell line, MMP-13 was most significantly up-regulated (Fig. 5A) as observed with RKO cells (Fig. 4A) . The expression of MMP-8, -9, -11, and -15 was also slightly upregulated with the knockdown of CITED2. Contrary to the slight upregulation of MMP-1 in CITED2-knockdown RKO cells, MMP-1 was downregulated in CITED2-knockdown SW480 cells (Fig. 5A) , suggesting the different genetic and epigenetic background of colon cancer cells might also contribute to CITED2 functions. To further determine whether CITED2 regulates SW480 invasiveness, we generated CITED2-knockdown stable cell line (Fig. 5B ) and performed Matrigel invasion assay. Boyden chamber invasion assay demonstrated that CITED2-knockdown significantly increased the invasiveness of SW480 cells (Fig. 5C) . Together, our data strongly support the notion that CITED2 regulates MMP-13 expression and invasiveness in colon cancer cell lines.
Butyrate upregulated CITED2 expression and
downregulated MMP-13 expression in colon cancer cells Numerous studies have shown that butyrate, a major dietary fermentation product and potent HDAC inhibitor, inhibits colon cancer invasion [25] [26] [27] . Research also suggests that MMPs expression can be epigenetically dysregulated as a result of histone hypoacetylation during tumor progression [28] . It is known that butyrate inhibits the expression of MMP-9 in colon cancer cells [27, 29] , and MMP-1 and MMP-13 in chondrocytes [30] . Thus, we tested whether butyrate regulated MMP-13 and/or CITED2 expression in RKO cells. As shown in Fig. 6A , butyrate upregulated CITED2 expression and downregulated MMP-13 expression in RKO cells. Reporter assays demonstrated strong activation of the CITED2 promoter by butyrate (Fig. 6B) . To explore whether there is a direct link between CITED2 and MMP-13 expression in colon cancer cells, we overexpressed HA-tagged CITED2 in RKO and SW480 cells. RT-PCR confirmed the overexpression of CITED2 in both cell lines. Ectopic expression of CITED2 was accompanied by downregulation of MMP-13 expression (Fig. 6C) . This observation was consistent with a previous report that overexpression of CITED2 represses MMP-13 expression in human chondrocytes [18] . The expression of MMP-1, -9 and other MMPs was not significantly affected by CITED2 overexpression (data not shown). Thus, butyrate stimulates CITED2 expression, and CITED2 expression is inversely correlated with MMP-13 expression in colon cancer cells.
CITED2 arrested cell growth when overexpressed in colon
cancer cells Having established that CITED2 expression is upregulated during stimulation to repress cell growth (Fig. 6) , we investigated its biological activity by overexpressing it in RKO cells. As transfection efficiency in RKO cells is low by conventional transient transfection, the cells were transfected with an empty vector (pCMV10) or HA-tagged CITED2 expression vector (pCMV10/HA-CITED2) followed by G418 selection to enrich the transfected cells. Using this approach, we observed a 2-to 3-fold increase of CITED2 mRNA in the enriched HA-CI-TED2-expressing RKO cells (data not shown). Because an anti-proliferative effect of CITED2 was apparent during the selection of the ''stable'' populations, we analyzed cell-cycle transition by flow cytometry. We found that ectopic expression of CITED2 arrested RKO cell growth (Fig. 7A) . Accordingly, overexpression of CITED2 increased cyclin-dependent kinase inhibitor p21 waf1 expression and significantly enhanced butyrate-induced p21 waf1 expression (Fig. 7B) . Among the CITEDs, CITED2 and CITED4 share some similarities. Firstly, both CITED2 and CITED4 are transcrip- tional co-repressors of HIF1a by competing with HIF1a for CBP/p300 binding [31] . HIF1a responsive genes are involved in many biological processes including angiogenesis, invasion/metastasis, cytoskeletal structure, and cell proliferation/ survival [32] . Secondly, both CITED2 and CITED4 also function as coactivators of transcription factor AP-2 by bridging the interaction between AP-2 and CBP/p300 [12, 33] . AP-2 is important to epithelial cells and has been implicated in activities such as mediation of growth arrest through activation of p21 waf1 [34] , maintenance of homotypic cell-cell adhesion through activation of E-cadherin [35] and promotion of apoptosis [36] . Fox et al. [31] documented that breast cancer development is characterized by either nuclear loss or cytoplasmic translocation of CITED4, with subsequent loss of HIF1a transcriptional antagonist activity. The striking similarities between CITED2 and CITED4 suggest a role for CITED2 in human tumorigenesis. A recent study showed that knockdown of CITED2 in breast cancer cell line MDA-MB-231 diminishes stimulation of MMP-9 and cell invasiveness by TGFb1 in vitro [18] . However, our study suggests that CITED2 might act as a repressor of colon cancer progression. In fact, we found that CITED2 suppressed colon cancer cell growth when overexpressed (data not shown). Thus, it may prove fruitful to study the function of CITED2 in other types of cancers and determine whether the state of CITED2 (e.g., expression and subcellular localization) changes during tumor progression. Collectively, our study provides a strong rationale for further exploring the roles of CITED2 in colon cancer progression and the possibilities of targeting CITED2 for chemoprevention and chemotherapy for colon cancer.
